Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

c-Rel is a myeloid checkpoint for cancer immunotherapy

Nature Cancer volume 1, pages 507–517 (2020)Cite this article

Subjects

Abstract

Immunotherapy that targets lymphoid cell checkpoints holds great promise for curing cancer. However, many cancer patients do not respond to this form of therapy. In addition to lymphoid cells, myeloid cells play essential roles in controlling immunity to cancer. Whether myeloid checkpoints exist that can be targeted to treat cancer is not well established. Here we show that c-Rel, a member of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family, specified the generation of myeloid-derived suppressor cells by selectively turning on protumoral genes while switching off antitumoral genes through a c-Rel enhanceosome. c-Rel deficiency in myeloid cells markedly inhibited cancer growth in mice and pharmaceutical inhibition of c-Rel had the same effect. Combination therapy that blocked both c-Rel and the lymphoid checkpoint protein programmed cell death protein 1 was more effective in treating cancer than blocking either alone. Thus, c-Rel is a myeloid checkpoint that can be targeted for treating cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Global and myeloid Rel gene deletion blocks tumor growth and reduces MDSCs in mice.
Fig. 2: Reduced suppressive function and altered metabolism of Rel−/− Gr-1+ myeloid cells.
Fig. 3: Loss of MDSC gene signatures from Rel−/− myeloid cells.
Fig. 4: c-Rel activates the MDSC signature genes Cebpb and Arg1.
Fig. 5: c-Rel regulates MDSC gene expression, metabolism and suppressive function via Cebpb.
Fig. 6: c-Rel inhibitor blocks tumor growth and MDSC development, and enhances the effect of anti-PD1 therapy.
Fig. 7: c-Rel inhibitor blocks human MDSCs.

Similar content being viewed by others

Data availability

Microarray and RNA-seq data that support the findings of this study have been deposited in the ArrayExpress under accession nos. E-MTAB-8674 and E-MTAB-8714. Source data for Fig. 1 and Figs. 4–7 are provided with this paper and are available online. All other data supporting the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133–150 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Manjili, M. H. Phenotypic plasticity of MDSC in cancers. Immunol. Invest. 41, 711–721 (2012).

    CAS  PubMed  Google Scholar 

  6. Solito, S., Pinton, L., Damuzzo, V. & Mandruzzato, S. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol. Invest. 41, 722–737 (2012).

    CAS  PubMed  Google Scholar 

  7. Trikha, P. & Carson, W. E. 3rd Signaling pathways involved in MDSC regulation. Biochim. Biophys. Acta 1846, 55–65 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Srivastava, M. K. et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7, e40677 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Stromnes, I. M. et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63, 1769–1781 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Steinberg, S. M. et al. Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors. Cancer Res. 77, 1599–1610 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 42, 1126–1130 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Trynka, G. et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling. Gut 58, 1078–1083 (2009).

    CAS  PubMed  Google Scholar 

  14. Gregersen, P. K. et al. REL, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat. Genet. 41, 820–823 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Hussman, J. P. et al. GWAS analysis implicates NF-κB-mediated induction of inflammatory T cells in multiple sclerosis. Genes Immun. 17, 305–312 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Himmelstein, D. S. & Baranzini, S. E. Heterogeneous network edge prediction: a data integration approach to prioritize disease-associated genes. PLoS Comput. Biol. 11, e1004259 (2015).

    PubMed  PubMed Central  Google Scholar 

  17. Beecham, A. H. et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Baranzini, S, E. et al. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am. J. Hum. Genet. 92, 854–865 (2013).

    Google Scholar 

  19. Simek, S. & Rice, N. R. Detection and characterization of the protein encoded by the chicken c-rel protooncogene. Oncogene Res. 2, 103–119 (1988).

    CAS  PubMed  Google Scholar 

  20. Grumont, R. J. & Gerondakis, S. The murine c-rel proto-oncogene encodes two mRNAs the expression of which is modulated by lymphoid stimuli. Oncogene Res. 5, 245–254 (1990).

    CAS  PubMed  Google Scholar 

  21. Artis, D. et al. Differential requirement for NF-κB family members in control of helminth infection and intestinal inflammation. J. Immunol. 169, 4481–4487 (2002).

    CAS  PubMed  Google Scholar 

  22. Carrasco, D. et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 187, 973–984 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Reinhard, K. et al. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection. Eur. J. Immunol. 41, 1388–1398 (2011).

    CAS  PubMed  Google Scholar 

  24. Harling-McNabb, L. et al. Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. Int. Immunol. 11, 1431–1439 (1999).

    CAS  PubMed  Google Scholar 

  25. Liou, H. C. et al. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int. Immunol. 11, 361–371 (1999).

    CAS  PubMed  Google Scholar 

  26. Köntgen, F. et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9, 1965–1977 (1995).

    PubMed  Google Scholar 

  27. Campbell, I. K., Gerondakis, S., O’Donnell, K. & Wicks, I. P. Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105, 1799–1806 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hilliard, B. A. et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 110, 843–850 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Lamhamedi-Cherradi, S.-E. et al. Transcriptional regulation of type I diabetes by NF-κB. J. Immunol. 171, 4886–4892 (2003).

    CAS  PubMed  Google Scholar 

  30. Wang, Y. et al. c-Rel is essential for the development of innate and T cell-induced colitis. J. Immunol. 180, 8118–8125 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Jordan, K. A., Dupont, C. D., Tait, E. D., Liou, H.-C. & Hunter, C. A. Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii. Int. Immunol. 22, 851–861 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Ruan, Q. et al. Development of Foxp3+ regulatory T cells is driven by the c-Rel enhanceosome. Immunity 31, 932–940 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Oh, H. An NF-κB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function. Immunity 47, 450–465.e5 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Grinberg-Bleyer, Y. et al. NF-κB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer. Cell 170, 1096–1108.e13 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Ruan, Q. et al. The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis. J. Exp. Med. 208, 2321–2333 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. & Gabrilovich, D. I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167–181 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Gato-Cañas, M. et al. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget 6, 27160–27175 (2015).

    PubMed  PubMed Central  Google Scholar 

  38. Chen Y. H., Murali R. & Sun J. Rel inhibitors and methods of use thereof. US patent 8609730 (PCT/US2009/030325) (2009).

  39. Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125, 3356–3364 (2015).

    PubMed  PubMed Central  Google Scholar 

  40. Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32, 790–802 (2010).

    CAS  PubMed  Google Scholar 

  41. Kaneda, M. M. et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Ostrand-Rosenberg, S., Sinha, P., Beury, D. W. & Clements, V. K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22, 275–281 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Srivastava, M. K. et al. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther. 2012, 7–12 (2012).

    PubMed  Google Scholar 

  44. Zilio, S. & Serafini, P. Neutrophils and granulocytic MDSC: the Janus god of cancer immunotherapy. Vaccines (Basel) 4, 31 (2016).

    Google Scholar 

  45. Zhao, Y., Wu, T., Shao, S., Shi, B. & Zhao, Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology 5, e1004983 (2016).

    PubMed  Google Scholar 

  46. Knopp, M. M., Löbmann, K., Elder, D. P., Rades, T. & Holm, R. Recent advances and potential applications of modulated differential scanning calorimetry (mDSC) in drug development. Eur. J. Pharm. Sci. 87, 164–173 (2016).

    CAS  PubMed  Google Scholar 

  47. Merika, M. & Thanos, D. Enhanceosomes. Curr. Opin. Genet. Dev. 11, 205–208 (2001).

    CAS  PubMed  Google Scholar 

  48. Panne, D. The enhanceosome. Curr. Opin. Struct. Biol. 18, 236–242 (2008).

    CAS  PubMed  Google Scholar 

  49. Arnosti, D. N. & Kulkarni, M. M. Transcriptional enhancers: intelligent enhanceosomes or flexible billboards? J. Cell. Biochem. 94, 890–898 (2005).

    CAS  PubMed  Google Scholar 

  50. Tumang, J. R. et al. c-Rel is essential for B lymphocyte survival and cell cycle progression. Eur. J. Immunol. 28, 4299–4312 (1998).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank H.-C. Liou (Cornell University), W. Weinberg (US FDA) and J. Zakrzewski (Cornell University) for providing the breeding pair of the Rel−/− mice. We thank D. Gabrilovich, J. Goldsmith, P. Fang, L. Wan, M. Lin, D. Zhang, L. Guan, J. Devergiilis and J. Sun for valuable discussions, technical support and reagents. We thank the University of Pennsylvania Pancreatic Islet Cell Biology Core and D.P. Beiting from the University of Pennsylvania School of Veterinary Medicine for technical support. This work was supported in part by grants from the National Institutes of Health (nos. R01-AI152195, R01-AI099216, R01-AI121166, R01-AI143676 and R01-AI136945 to Y.H.C.); X.L. was partially supported by grant no. NIH-T32-DK007780.

Author information

Author notes

  1. These authors contributed equally: Ting Li, Xinyuan Li.

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Ting Li, Xinyuan Li, Ali Zamani, Wei Wang, Chin-Nien Lee, Mingyue Li, George Luo, Emily Eiler, Honghong Sun & Youhai H. Chen

  2. Department of Microbiology and Immunology, College of Physicians & Surgeons, Columbia University, New York, NY, USA

    Sankar Ghosh

  3. Mount Sinai Center for Therapeutics Discovery, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jian Jin

  4. Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jian Jin

  5. Department of Biomedical Sciences, Research Division of Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Ramachandran Murali

  6. Shandong Eye Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    Qingguo Ruan & Weiyun Shi

Authors
  1. Ting Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Zamani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chin-Nien Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mingyue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. George Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Emily Eiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Honghong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sankar Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jian Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ramachandran Murali
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Qingguo Ruan
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Weiyun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Youhai H. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T.L. and X.L. designed and executed the experiments and wrote the manuscript. A.Z. designed and performed some of the MDSC suppression experiments. H.S., M.L., W.W., C.-N.L., G.L., E.E., Q.R. and W.S. helped complete certain molecular, cellular or animal experiments. S.G. provided the Rel gene floxed mice. J.J. and R.M. designed and optimized the c-Rel inhibitor. Y.H.C. conceived and supervised the study and wrote the manuscript.

Corresponding author

Correspondence to Youhai H. Chen.

Ethics declarations

Competing interests

Y.H.C. and R.M. are inventors of the following patent that describes the c-Rel inhibitor used in this study: Chen Y.H., Murali R. & Sun J. Rel inhibitors and methods of use thereof (USA patent no. US8609730B2). Y.H.C. is a member of the advisory board of Amshenn Pharmaceutical Company and Binde Company.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Global and myeloid Rel gene deletion blocks tumor growth and reduces MDSCs in mice.

a, Tumor growth in WT and Rel−/− mice (n = 5 mice/group) injected s.c. with B16F0 tumor cells (***, P < 0.0001). b, Tumor weight of WT and Rel−/− mice (n = 10 mice/group) treated in Fig. 1a. (*, P = 0.0188). c, Percentages of CD11b+Gr-1+ cells in the blood of WT and Rel−/− mice treated with anti-Gr-1 or IgG isotype control (n = 3 mice/group), 7 days post B16F10 tumor cell inoculation (**, P = 0.0037; ***, P < 0.0001). d, Percentages of CD11b+Gr-1+ cells in the tumor of WT mice treated with anti-Gr-1 or IgG isotype control (n = 3 mice/group), 7 days post B16F10 tumor cell inoculation (***, P = 0.0008). e, Percentages of CD4+CD25+ cells in the spleen of WT and Rel−/− mice treated with anti-CD25 or IgG isotype control (n = 3 mice/group), 14 days post B16F10 tumor cell inoculation (***, P < 0.0001). f, Tumor size on Day 14 of WT and Rel−/− mice treated as in Fig. 1c–e. n = 16 for the WT + IgG group, n = 15 for the Rel−/−+IgG group, n = 11 for the WT + anti-Gr1 group, n = 10 for the Rel−/−+anti-Gr1 group, n = 9 for the WT + anti-CD25 group, and n = 9 for the Rel−/−+anti-CD25 group (*, P = 0.0303; **, P < 0.01; ***, P = 0.0001). g, c-Rel expression in Gr-1+ and Gr-1- splenocytes of LyzM-Cre (Cre) and LyzM-Cre RelF/F (RelF/F) tumor-bearing mice as determined by Western blot. Representative blots from biologically independent experiments were shown and the bar graph shows the relative quantities of the c-Rel protein in the corresponding group shown below (n = 3 mice for each group; *, P = 0.0101). h,i, Percentages of CD11b+Ly6G+ (h) and CD11b+Ly6C+ (i) leukocytes in the tumor of WT and Rel−/− mice treated in Fig. 1a (n = 5 mice/group). **, P = 0.0011 for panel h; **, P = 0.0087 for panel i. j, Percentages of CD8+CD25+ leukocytes in the tumor of LyzM-Cre and LyzM-Cre RelF/F mice treated in Fig. 1f (n = 8 mice/group; ***, P = 0.0005). k-n, Percentages of the indicated leukocyte subsets in the spleen of WT and Rel−/− mice treated in Fig. 1a. (n = 4 mice/group in the panels k and l; n = 5 mice/group in the panels m and n; *, P = 0.037). Statistical significance was determined by two-tailed Mann-Whitney U-test (a), two-tailed unpaired t-test (b-f, h-j, m), or one-way ANOVA with Tukey post-hoc test (g). For all panels, data are presented as means ± s.e.m.

Source data

Extended Data Fig. 2 Percentages of immune cell subsets in tumor-bearing and naïve LyzM-Cre and LyzM-Cre RelF/F mice.

a, Percentages of CD11b+Gr-1+ cells in the spleen of mice treated in Fig. 1f. n = 6 mice/group. b-d, Percentages of CD4+ cells in the spleen (b, n = 6/group), blood (c, n = 6/group), and tumor (d, n = 8/group) of mice treated in Fig. 1f. e-g, Percentages of CD4+CD25+ cells in the spleen (e, n = 6/group), blood (f, n = 6 for the LyzM-Cre group and n = 5 for the LyzM-Cre RelF/F group), and tumor (g, n = 3 for the LyzM-Cre group and n = 6 for the LyzM-Cre RelF/F group) of mice treated in Fig. 1f. h-j, Percentages of CD8+ cells in the spleen (h, n = 6/group), blood (i, n = 6/group), and tumor (j, n = 8/group) of mice treated in Fig. 1f. k-n, Percentages of the indicated leukocyte subsets in the tumor (n = 3 for the LyzM-Cre group and n = 6 for the LyzM-Cre RelF/F group) of mice treated in Fig. 1f (k, l), and the spleen (n = 3 for the LyzM-Cre group and n = 5 for the LyzM-Cre RelF/F group) of naïve mice (m, n). (***, P = 0.0002) Statistical significance was determined by two-tailed unpaired t-test (k). For all panels, data are presented as means ± s.e.m.

Source data

Extended Data Fig. 3 Reduced suppressive function, reactive oxygen species (ROS) production, and cell growth in Rel−/− MDSCs.

a,b, Representative flow cytometry plots from the MDSC-T cell suppression assay for Fig. 2a (a) and Fig. 2b (b). c, Growth of bone marrow-derived MDSCs from WT (n = 4 mice/group) and Rel−/− (n = 9 mice/group) mice. (*, P = 0.03299). d, ROS production by bone marrow-derived MDSCs from WT and Rel−/− mice (n = 6 mice/group; ***, P < 0.0001). e, Percentages of CD11b+Ly6G+ and CD11b+Ly6C+ cells in bone marrow-derived MDSCs from WT and Rel−/− mice. Data representative of three independent experiments. f, Tumor growth in WT mice injected s.c. with B16F10 tumor cells plus Rel−/− MDSCs infected with control (n = 5 mice) or Rel-expressing retroviruses (n = 6 mice) (**, P = 0.0041). g, Percentages of CD44high cells in intratumor CD8+ cells of WT mice treated as in panel f. (n = 4 mice/group; *, P = 0.0187). h, The degree of suppression, at the indicated Effector:T cell ratio, of CD8+ T cell proliferation by bone marrow-derived MDSCs and BMDMs from naïve mice (n = 3 mice/group). The concentrations of anti-CD3 and anti-CD28 used (125 ng/mL each) were half of those in Fig. 2b (***, P < 0.0001). i, Representative flow cytometry plots for the MDSC-T cell suppression assay for Panel h. Statistical significance was determined by two-tailed unpaired t-test (c-e, g), two-tailed Mann-Whitney U-test (f), or two-way ANOVA with Tukey post-hoc test (h). Data are presented as means ± s.e.m. (c,d,f,h).

Source data

Extended Data Fig. 4 Rel gene deletion in MDSCs leads to upregulated expression of inflammatory genes and decreased Cebpb downstream genes.

a,b, Results from Ingenuity Pathway analysis of the RNA-seq data of bone marrow-derived WT and Rel−/− MDSCs, showing upregulated ‘inflammatory response’ genes (a, red) and downregulated Cebpb downstream genes (b, green) in Rel−/− MDSCs. Statistical significance was determined by calculated a right-tailed Fisher’s Exact Test. All data are pooled from 3 independent experiments.

Extended Data Fig. 5 Rel gene deletion in macrophages results in decreased expression of inflammatory genes.

BMDMs from WT and Rel−/− mice were treated with vehicle or LPS (100 ng/mL) for 1 hour and gene microarray analysis was performed for ~30,000 murine genes. Ingenuity Pathway Analysis was performed to identify c-Rel-regulated genes that were downstream of LPS response. Blue genes were decreased, and red genes were increased in Rel−/− cells as compared to WT cells, after LPS treatment.

Extended Data Fig. 6 The inhibitor is c-Rel-specific and blocks MDSC suppressive functions.

a, Relative numbers of WT and Rel−/− human Jurkat T cells treated with the c-Rel inhibitor (2.5 μM) or vehicle for the indicated times (n = 3 biologically independent cultures/group). b,c, Relative numbers of EL4 (b, n = 3 biologically independent cultures/group) and B16F10 (c, n = 3 biologically independent cultures/group) cells treated with or without the c-Rel inhibitor (5 μM) (**, P = 0.00767). d,e, Relative mRNA levels of IL-2 in WT, Rel−/− human Jurkat T cells (d, n = 3 biologically independent cultures/group; **, P = 0.0047), and normal human PBMCs (e, n = 3 biologically independent cultures/group; *, P = 0.0241) that were treated with or without c-Rel inhibitor (1 μM). For stimulation, plate-coated anti-mouse CD3 (250 ng/ml) plus soluble anti-mouse CD28 (250 ng/ml), or PMA (10 ng/ml) plus ionomycin (1 µM) were added to the culture for 4 hours, as indicated. f, Preferential inhibition of c-Rel binding to DNA by the c-Rel inhibitor. Western blot for the indicated NF-κB proteins after the NF-κB oligonucleotide pull-down of the nuclear extracts of WT and Rel−/− splenocytes treated with the c-Rel inhibitor (5 µM) or vehicle control (Ctr). g, Body weight change of mice that were injected i.p. with vehicle control only (n = 7 mice), or injected s.c. with B16F10 cells and i.p. with the c-Rel inhibitor (n = 3 mice) or vehicle control (n = 4 mice) as indicated. h,i, Representative flow cytometry plots of the MDSC-T cell suppression assay for Fig. 6e (h) and Fig. 6f (i). Data are presented as means ± s.e.m (a-e, g, and i). n = 3 mice/group (d,e,j). Statistical significance was determined by two-tailed unpaired t-test (b-e).

Source data

Supplementary information

Supplementary Information

Supplementary Tables 1 and 2.

Reporting Summary

Source data

Source Data Fig. 1

Statistical source data.

Source Data Fig. 2

Statistical source data.

Source Data Fig. 4

Unprocessed western blots and gels.

Source Data Fig. 4

Statistical source data.

Source Data Fig. 5

Unprocessed gels.

Source Data Fig. 5

Statistical source data.

Source Data Fig. 6

Statistical source data.

Source Data Fig. 7

Statistical source data.

Source Data Extended Data Fig. 1

Unprocessed western blots.

Source Data Extended Data Fig. 1

Statistical source data.

Source Data Extended Data Fig. 2

Statistical source data.

Source Data Extended Data Fig. 3

Statistical source data.

Source Data Extended Data Fig. 6

Unprocessed western blots.

Source Data Extended Data Fig. 6

Statistical source data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, T., Li, X., Zamani, A. et al. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nat Cancer 1, 507–517 (2020). https://doi.org/10.1038/s43018-020-0061-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-020-0061-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer